MeiraGTx receives RPDD from FDA for AAV8-RK-RetGC program

MeiraGTx (MGTX) announced the U.S. Food and Drug Administration, FDA, has granted the Company Rare Pediatric Disease Designation, RPDD, to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations. This is the fourth Rare Pediatric Disease Designation the Company has received in the last three months, including AAV8-RK-AIPL1 for the treatment of LCA4 retinal dystrophy, AAV8-RK-BBS10 for the treatment of Bardet-Biedl syndrome due to BBS10 mutations and AAV5-RDH12 for the treatment of RDH12 associated retinal dystrophy.